Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

2.

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 24;13:2557-2568. doi: 10.2147/COPD.S169958. eCollection 2018.

3.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

4.

GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.

Worth H, Buhl R, Criée CP, Kardos P, Lossi NS, Vogelmeier CF.

Respir Med. 2017 Oct;131:77-84. doi: 10.1016/j.rmed.2017.08.008. Epub 2017 Aug 9.

5.

A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study.

Kardos P, Vogelmeier C, Worth H, Buhl R, Lossi NS, Mailänder C, Criée CP.

Respir Med. 2017 Mar;124:57-64. doi: 10.1016/j.rmed.2017.02.007. Epub 2017 Feb 16.

6.

"Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.

Vogelmeier C, Worth H, Buhl R, Criée CP, Lossi NS, Mailänder C, Kardos P.

Int J Chron Obstruct Pulmon Dis. 2017 Feb 1;12:487-494. doi: 10.2147/COPD.S125616. eCollection 2017.

7.

Coevolution of the ATPase ClpV, the sheath proteins TssB and TssC, and the accessory protein TagJ/HsiE1 distinguishes type VI secretion classes.

Förster A, Planamente S, Manoli E, Lossi NS, Freemont PS, Filloux A.

J Biol Chem. 2014 Nov 21;289(47):33032-43. doi: 10.1074/jbc.M114.600510. Epub 2014 Oct 10.

8.

A visual assay to monitor T6SS-mediated bacterial competition.

Hachani A, Lossi NS, Filloux A.

J Vis Exp. 2013 Mar 20;(73):e50103. doi: 10.3791/50103.

9.

The HsiB1C1 (TssB-TssC) complex of the Pseudomonas aeruginosa type VI secretion system forms a bacteriophage tail sheathlike structure.

Lossi NS, Manoli E, Förster A, Dajani R, Pape T, Freemont P, Filloux A.

J Biol Chem. 2013 Mar 15;288(11):7536-48. doi: 10.1074/jbc.M112.439273. Epub 2013 Jan 22.

10.

The archetype Pseudomonas aeruginosa proteins TssB and TagJ form a novel subcomplex in the bacterial type VI secretion system.

Lossi NS, Manoli E, Simpson P, Jones C, Hui K, Dajani R, Coulthurst SJ, Freemont P, Filloux A.

Mol Microbiol. 2012 Oct;86(2):437-56. doi: 10.1111/j.1365-2958.2012.08204.x. Epub 2012 Aug 29.

11.

Structure-function analysis of HsiF, a gp25-like component of the type VI secretion system, in Pseudomonas aeruginosa.

Lossi NS, Dajani R, Freemont P, Filloux A.

Microbiology. 2011 Dec;157(Pt 12):3292-305. doi: 10.1099/mic.0.051987-0. Epub 2011 Aug 26.

12.

Type VI secretion system in Pseudomonas aeruginosa: secretion and multimerization of VgrG proteins.

Hachani A, Lossi NS, Hamilton A, Jones C, Bleves S, Albesa-Jové D, Filloux A.

J Biol Chem. 2011 Apr 8;286(14):12317-27. doi: 10.1074/jbc.M110.193045. Epub 2011 Feb 16.

13.

The Salmonella SPI-2 effector SseJ exhibits eukaryotic activator-dependent phospholipase A and glycerophospholipid : cholesterol acyltransferase activity.

Lossi NS, Rolhion N, Magee AI, Boyle C, Holden DW.

Microbiology. 2008 Sep;154(Pt 9):2680-8. doi: 10.1099/mic.0.2008/019075-0.

Supplemental Content

Loading ...
Support Center